Malignant Hyperthermia Awareness and Training Month

Categories:: Health
Tags:: Appreciation Awareness Educational
Where:: United States
Date change rule:: Every March
Holiday emoji:: 🩺

Malignant Hyperthermia Awareness and Training Month takes place throughout March, dedicated to shedding light on this rare, life-threatening genetic disorder. This observance highlights the importance of early diagnosis, understanding triggers, and ensuring healthcare professionals receive critical training to manage MH crises. Learn about symptoms, support research, and advocate for better patient care.

Deals
Platforms
Social
Brands
Hero
History
Timeline
Businesses
FAQs
Importance
Observe

Expected Malignant Hyperthermia Awareness and Training Month Deals

Throughout Malignant Hyperthermia Awareness and Training Month, the focus shifts from commercial deals to vital fundraising and educational initiatives. Organizations like the Malignant Hyperthermia Association of the United States (MHAUS) lead campaigns for donations to support research, patient advocacy, and professional training. Medical device companies such as Baxter International and GE Healthcare may partner with healthcare systems to offer discounted training programs or educational materials on MH management. Pharmaceutical companies like Par Pharmaceutical, which produces dantrolene (the only specific treatment for MH), might sponsor educational webinars. Hospitals and medical centers often host free public seminars or offer continuing education credits for nurses and anesthesiologists. Look for opportunities to donate directly to research funds or participate in virtual awareness events. We will update this page with confirmed live initiatives as March approaches.

Platform Guide for Malignant Hyperthermia Awareness and Training Month

Tag National Today (linkedin.com/company/nationaltoday) and use #MHAwarenessMonth. Share professional insights, training opportunities, and research updates relevant to healthcare workers.

X/Twitter

Mention @NatlToday and use #MHAwarenessMonth. Post quick facts about MH, share links to educational resources, and amplify patient stories to reach a broad audience.

Facebook

Mention National Today (facebook.com/nationaltoday) and use #MHAwarenessMonth. Create community discussions around MH, share personal experiences, and promote local awareness events.

Malignant Hyperthermia Awareness and Training Month Hero

Dr. Henry Rosenberg

Dr. Henry Rosenberg is a pioneering anesthesiologist and a co-founder of the Malignant Hyperthermia Association of the United States (MHAUS). His extensive research and advocacy have been instrumental in advancing the understanding, diagnosis, and treatment of MH. Through his work, Dr. Rosenberg has significantly improved patient safety and outcomes for individuals susceptible to this rare genetic disorder, impacting countless lives globally.

History of Malignant Hyperthermia Awareness and Training Month

Malignant Hyperthermia was an unknown condition back in the early 1960s when it mysteriously took the lives of many patients. The nature of the disease was described as patients experiencing a rapid increase in body temperature while under anesthesia until their bodies could no longer handle it. However, a clearer picture of the disease was given in the mid-1960s when a man from Melbourne, Australia, with a history of family deaths, presented a compound fracture that he had gotten while under anesthesia. Similar cases were reported all around the world since then and in 1966, Dr. Robert A. Gordon named the disease ‘malignant hyperthermia.’ Together with Dr. Beverly Britt, he organized the first symposium on malignant hyperthermia, which was documented and published in the 1966 Canadian Journal of Anesthesiology.

By the mid-1980s, besides a high temperature, symptoms of malignant hyperthermia also included acidosis, muscle rigidity, and breakdown, which is why the treatment of the condition includes dantrolene, a muscle relaxer.

By the late-1980s, a strange observation occurred when a patient with Duchenne muscular dystrophy (D.M.D.) showed symptoms of malignant hyperthermia when anesthetized. Neuroleptic malignant syndrome (N.M.S.) is also another syndrome that displays classic symptoms of malignant hyperthermia.

A major breakthrough in the malignant hyperthermia study happened in 1990 when David MacLennan of the University of Toronto found that pigs were also susceptible to this disease as a result of a special mutation in their genes. Today, scientists all over the world continue their research to further develop ways to prevent and manage malignant hyperthermia.

Malignant Hyperthermia Awareness and Training Month timeline

Early 1960s

The Unknown Condition that Killed Anesthetized Patients

Malignant hyperthermia is still an unknown condition that causes the deaths of patients under anesthesia.

1966

The First Malignant Hyperthermia Symposium

Dr. R. A. Gordona and Dr. B. Britt conduct the first symposium discussing the symptoms of malignant hyperthermia.

1980s

The Symptoms of Malignant Hyperthermia

The symptoms of malignant hyperthermia are determined, which include high temperature, acidosis, and muscle rigidity and breakdown.

2009

Further Findings on the Symptoms

Dr. Susan Hamilton at Baylor University finds that genetically engineered mice with RYR1 develop malignant hyperthermia syndrome after heat exposure.

How Businesses Can Celebrate Malignant Hyperthermia Awareness and Training Month

Local healthcare businesses, from independent clinics to large hospital systems, can actively participate in Malignant Hyperthermia Awareness and Training Month. Host educational seminars for staff and the public, focusing on early recognition and emergency protocols for MH. Offer specialized training sessions for anesthesiologists and nurses, perhaps with simulation exercises. Partner with organizations like MHAUS to distribute awareness materials, such as patient safety cards and informational brochures. Consider dedicating a portion of March’s proceeds to MH research or providing free genetic counseling services for at-risk families. Raising awareness among medical professionals and the community is paramount.

Malignant Hyperthermia Awareness and Training Month FAQs

When is Malignant Hyperthermia Awareness and Training Month?

In 2027, Malignant Hyperthermia Awareness and Training Month will again be observed throughout March. It’s an annual opportunity to reinforce knowledge about this rare and potentially fatal genetic disorder.

How many people are affected by Malignant Hyperthermia?

While precise numbers vary, MH susceptibility is estimated to occur in about 1 in 2,000 to 1 in 100,000 surgical patients. Awareness campaigns aim to identify more at-risk individuals and prevent adverse events.

What are the common triggers for Malignant Hyperthermia?

The most common triggers for MH are specific inhalation anesthetics and succinylcholine, used during surgery. Recognizing these triggers is crucial for preventing an MH crisis, as avoiding them in susceptible individuals is the primary preventive measure.

Is Malignant Hyperthermia a genetic condition?

MH is indeed a genetic condition, typically inherited in an autosomal dominant pattern. This means that if one parent carries the mutated gene, there’s a 50% chance their child will inherit MH susceptibility, making family history a critical diagnostic tool.

How to Observe Malignant Hyperthermia Awareness and Training Month

Attend symposiums
The study and development of malignant hyperthermia management is a work in progress. Join symposiums and seminars to get informed about the symptoms and ways to manage this illness.
Join training
Healthcare professionals are encouraged to attend malignant hyperthermia crisis management training as a way to handle future patients. Find out if you can attend at your local hospital and medical facility to gain a better understanding of the condition.
Donate to non-profit organizations
Non-profit organizations such as the Malignant Hyperthermia Association of the U.S. (MHAUS,) accept small donations to promote optimum care for patients living with the disease and conduct further research for improved scientific understanding. Any amount could potentially save a life.

5 Important Facts About Malignant Hyperthermia

Malignant hyperthermia is hereditary
It’s an inherited syndrome that triggers patients who receive general anesthesia.
Dantrolene helps
The only clinically approved drug that helps relax the muscles of malignant hyperthermia patients, who are experiencing symptoms, is Dantrolene.
Pre-anesthesia assessment
It’s required for patients to disclose any family history of malignant hyperthermia during a pre-anesthesia assessment.
The onset happens fast
The symptoms of malignant hyperthermia occur rapidly, requiring healthcare professionals to respond urgently.
Genetic testing is available
You can find out if you’re susceptible through several genetic testing sites in the country.

Why Malignant Hyperthermia Awareness and Training Month is Important

It raises awareness
Since malignant hyperthermia is a relatively unknown disease, this month-long observance helps to inform the general public about the condition. Knowledge is key in treating and managing this illness.
It helps research funding
Continuous research and development for the management of malignant hyperthermia are essential. People showing support through donations tremendously help scientists and researchers to continue with the progress they’ve made in determining the most effective ways to treat this disease.
It makes malignant hyperthermia patients feel seen
In raising awareness around malignant hyperthermia, patients are less likely to be stigmatized. This eliminates the fear of judgment that they may experience on top of having to deal with the disease.